MPN Watch

Dossier web other 2026

EHA 2026 | Top abstracts in MPN

Key claim: The MPN Hub Steering Committee identified top abstracts for EHA 2026 spanning JAK inhibitors, hepcidin mimetics, immune modulators, and major trials across PV, ET, and myelofibrosis.

Abstract

The MPN Hub Steering Committee provided recommendations for top abstracts to look out for in MPN at EHA 2026, covering multiple therapeutic areas including JAK inhibitors, hepcidin mimetics, immune modulators, and trials like MANIFEST, SIMPLIFY-2, MOMENTUM, REVEAL, and others across PV, ET, and myelofibrosis.

Why this matters

Pending synthesis.

Source

Link

Briefing card

EHA 2026 | Top abstracts in MPN
Stage: other · web · 2026

The MPN Hub Steering Committee identified top abstracts for EHA 2026 spanning JAK inhibitors, hepcidin mimetics, immune modulators, and major trials across PV, ET, and myelofibrosis.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://mpn-hub.com/medical-information/eha2026-top-abstracts-in-mpn

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Subscribe: calendar of upcoming dates · deadlines feed · all new records · Help

build build 612 · 69ce4cf-dirty · 2026-11-11